T Hajek1, M Bauer2, C Simhandl3, J Rybakowski4, C O'Donovan1, A Pfennig2, B König3, A Suwalska4, K Yucel5, R Uher1, L T Young6, G MacQueen7, M Alda1. 1. Department of Psychiatry, Dalhousie University, Halifax, NS, Canada. 2. Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany. 3. Psychiatrische Abteilung, Krankenhaus Neunkirchen, Austria. 4. Department of Adult Psychiatry, Poznan University of Medical Sciences, Poland. 5. Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada. 6. Department of Psychiatry, University of Toronto, ON, Canada. 7. Department of Psychiatry, University of Calgary, AB, Canada.
Abstract
BACKGROUND: Neuroimaging studies have demonstrated an association between lithium (Li) treatment and brain structure in human subjects. A crucial unresolved question is whether this association reflects direct neurochemical effects of Li or indirect effects secondary to treatment or prevention of episodes of bipolar disorder (BD). METHOD: To address this knowledge gap, we compared manually traced hippocampal volumes in 37 BD patients with at least 2 years of Li treatment (Li group), 19 BD patients with <3 months of lifetime Li exposure over 2 years ago (non-Li group) and 50 healthy controls. All BD participants were followed prospectively and had at least 10 years of illness and a minimum of five episodes. We established illness course and long-term treatment response to Li using National Institute of Mental Health (NIMH) life charts. RESULTS: The non-Li group had smaller hippocampal volumes than the controls or the Li group (F 2,102 = 4.97, p = 0.009). However, the time spent in a mood episode on the current mood stabilizer was more than three times longer in the Li than in the non-Li group (t(51) = 2.00, p = 0.05). Even Li-treated patients with BD episodes while on Li had hippocampal volumes comparable to healthy controls and significantly larger than non-Li patients (t(43) = 2.62, corrected p = 0.02). CONCLUSIONS: Our findings support the neuroprotective effects of Li. The association between Li treatment and hippocampal volume seems to be independent of long-term treatment response and occurred even in subjects with episodes of BD while on Li. Consequently, these effects of Li on brain structure may generalize to patients with neuropsychiatric illnesses other than BD.
BACKGROUND: Neuroimaging studies have demonstrated an association between lithium (Li) treatment and brain structure in human subjects. A crucial unresolved question is whether this association reflects direct neurochemical effects of Li or indirect effects secondary to treatment or prevention of episodes of bipolar disorder (BD). METHOD: To address this knowledge gap, we compared manually traced hippocampal volumes in 37 BD patients with at least 2 years of Li treatment (Li group), 19 BD patients with <3 months of lifetime Li exposure over 2 years ago (non-Li group) and 50 healthy controls. All BD participants were followed prospectively and had at least 10 years of illness and a minimum of five episodes. We established illness course and long-term treatment response to Li using National Institute of Mental Health (NIMH) life charts. RESULTS: The non-Li group had smaller hippocampal volumes than the controls or the Li group (F 2,102 = 4.97, p = 0.009). However, the time spent in a mood episode on the current mood stabilizer was more than three times longer in the Li than in the non-Li group (t(51) = 2.00, p = 0.05). Even Li-treated patients with BD episodes while on Li had hippocampal volumes comparable to healthy controls and significantly larger than non-Li patients (t(43) = 2.62, corrected p = 0.02). CONCLUSIONS: Our findings support the neuroprotective effects of Li. The association between Li treatment and hippocampal volume seems to be independent of long-term treatment response and occurred even in subjects with episodes of BD while on Li. Consequently, these effects of Li on brain structure may generalize to patients with neuropsychiatric illnesses other than BD.
Authors: Nikita Nogovitsyn; Meghan Muller; Roberto Souza; Stefanie Hassel; Stephen R Arnott; Andrew D Davis; Geoffrey B Hall; Jacqueline K Harris; Mojdeh Zamyadi; Paul D Metzak; Zahinoor Ismail; Jonathan Downar; Sagar V Parikh; Claudio N Soares; Jean M Addington; Roumen Milev; Kate L Harkness; Benicio N Frey; Raymond W Lam; Stephen C Strother; Susan Rotzinger; Sidney H Kennedy; Glenda M MacQueen Journal: Neuropsychopharmacology Date: 2019-10-14 Impact factor: 7.853
Authors: Isabelle E Bauer; Marsal Sanches; Robert Suchting; Charles E Green; Nadia M El Fangary; Giovana B Zunta-Soares; Jair C Soares Journal: J Psychiatr Res Date: 2014-09-10 Impact factor: 4.791
Authors: Isabelle E Bauer; Austin Ouyang; Benson Mwangi; Marsal Sanches; Giovana B Zunta-Soares; Richard S E Keefe; Hao Huang; Jair C Soares Journal: J Psychiatr Res Date: 2015-02-07 Impact factor: 4.791
Authors: C I Giakoumatos; P Nanda; I T Mathew; N Tandon; J Shah; J R Bishop; B A Clementz; G D Pearlson; J A Sweeney; C A Tamminga; M S Keshavan Journal: J Psychiatr Res Date: 2014-12-23 Impact factor: 4.791
Authors: Tomas Hajek; Katja Franke; Marian Kolenic; Jana Capkova; Martin Matejka; Lukas Propper; Rudolf Uher; Pavla Stopkova; Tomas Novak; Tomas Paus; Miloslav Kopecek; Filip Spaniel; Martin Alda Journal: Schizophr Bull Date: 2019-01-01 Impact factor: 9.306